Granhall C, Donsmark M, Blicher TM, Golor G, Sndergaard FL, Thomsen M, et al
Mounjaro (Tirzepatide) Injection can potentially cause low blood sugar levels, especially when used in combination with other diabetes medications like insulin or sulfonylureas
These injections contain a medication called Tirzepatide, which is a dual GIP and GLP-1 receptor agonist
Sugar alcohols and artificial sweeteners: the stealth disruptors This is the food category that flies under the radar
However, injection site reactions occur in 2-10% of patients, and rare allergic skin reactions including rash, hives, and itching have been documented
Blood pressure reductions with tirzepatide are typically observed within weeks to months of treatment initiation and are maintained throughout long-term therapy